Institut De Recherches Internationales Servier

This phase 3 study tests whether a combination of trifluridine/tipiracil (a chemotherapy pill) and bevacizumab (a targeted therapy) works better than the current standard of capecitabine plus bevacizumab for people with metastatic colorectal cancer who are not healthy enough for …

This study tests a new drug, vorasidenib, combined with a standard chemotherapy (temozolomide) for people with a specific type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to find the safest dose and see if the combination helps control the tumor. About …

This study was designed to test a new drug called S095033 combined with the chemotherapy paclitaxel in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to see if the combination was safe and could shrink tumors. However, the trial was withdrawn …

This early-stage study tests whether combining two drugs—vorasidenib and pembrolizumab—can help people with a specific type of brain tumor (IDH-1 mutant glioma) that has come back or is growing. About 60 adults with grade 2 or 3 tumors will receive the treatment before and after …

This early-stage study is testing the safety of two experimental drugs, AG-120 and AG-221, when given together with standard chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (IDH1 or IDH2 mutation). The study involves ab…

This study tests whether adding the targeted drug ivosidenib (AG-120) to standard azacitidine helps adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML) who are not healthy enough for strong chemotherapy. About 146 participants received either the drug…